Size, depth, differentiation, and the staging systems that flag aggressive tumors (BWH and AJCC8)
Bring a printable list of questions to your appointment, or share this page with someone who needs it.
Most cutaneous squamous cell carcinomas (SCCs) are low-risk: removed once, they do not come back and never threaten anything beyond the skin. A minority behave differently — recurring after treatment, invading nerves or bone, or spreading to lymph nodes. "High-risk" is the label doctors use for tumors that carry a meaningfully raised chance of doing one of those things, and it is based on specific, measurable features rather than a hunch.
This page walks through the individual features that raise risk, then explains the two tumor-staging systems — the AJCC 8th edition and the Brigham and Women's Hospital (BWH) system — that clinicians use to combine those features into a stage. For how stage and grade fit together more broadly, see SCC staging and grading.
No single feature makes a tumor dangerous on its own, but the more of these that are present, the higher the risk of recurrence, nodal spread, and death from disease. Guidelines from the American Academy of Dermatology and the National Comprehensive Cancer Network draw on the same core list.
A tumor 2 cm or larger is considered high-risk, and one 4 cm or larger higher still. Size on the head and neck carries extra weight because there is less room before a tumor reaches cartilage, bone, or nerves.
Invasion beyond about 6 mm deep, or past the subcutaneous fat into muscle, cartilage, or bone, marks a tumor as high-risk. Bone invasion is one of the strongest single predictors of a poor outcome.
A pathologist grades how closely the cancer cells still resemble normal squamous cells. Poorly differentiated (high-grade) tumors look markedly abnormal and are an independent risk factor — a small poorly differentiated tumor can be more concerning than a larger well-differentiated one.
Cancer growing along a nerve. Involvement of a larger nerve (roughly 0.1 mm in caliber or bigger), or of a named nerve, is what counts as a high-risk feature and can change the surgical plan and add radiation. See what perineural invasion means for your SCC.
Infiltrative, single-cell, or desmoplastic growth patterns send roots well past the visible edge and recur more often. Cancer seen inside small blood or lymph vessels (lymphovascular invasion) also raises concern for spread.
The ear and the hair-bearing lip are classic high-risk sites. Tumors on previously irradiated skin, in old burn scars or chronic wounds, or on areas of the central face also behave more aggressively. See SCC in high-risk locations.
A tumor that has already recurred after treatment, and a tumor arising in someone who is immunosuppressed — a solid-organ transplant recipient, or a person with chronic lymphocytic leukemia or lymphoma — both carry a substantially higher risk of recurrence and spread.
To turn that list of features into something consistent, pathologists and oncologists assign a tumor (T) stage. Two systems are in common use, and they are not interchangeable.
The American Joint Committee on Cancer manual, 8th edition, is the official U.S. system, but its cutaneous SCC chapter was written only for tumors of the head and neck. It stages mainly by size, with a few features that push a tumor higher:
The BWH system counts four high-risk factors: tumor diameter 2 cm or larger, poorly differentiated histology, perineural invasion of a nerve 0.1 mm or larger in caliber, and tumor invasion beyond the subcutaneous fat. The T stage is simply how many are present:
In validation studies, BWH stage T2b and T3 tumors are a small fraction of all SCCs but account for the large majority of nodal metastases and deaths — which is why many skin-cancer centers use BWH alongside, or instead of, AJCC8.
AJCC8's T3 category is broad — a 4 cm tumor with no other worrying features lands in the same group as one with perineural and deep invasion — so it does not separate moderate risk from severe risk very sharply. Studies comparing the systems found that BWH more precisely concentrated the poor outcomes into its highest stages, giving a clearer picture of who actually needs aggressive treatment and close surveillance.
Guideline groups add their own layer. The NCCN sorts SCC into low-, high-, and very-high-risk categories using a longer checklist that also includes location, recurrence, rapid growth, neurologic symptoms, immunosuppression, and prior radiation. Independent validation has supported that the very-high-risk group carries markedly worse outcomes. In practice your care team may cite an AJCC stage, a BWH stage, and an NCCN risk category — they are describing the same tumor through three lenses.
Landing in a high-risk category does not mean the cancer has spread. It means your team will treat the tumor more thoroughly and watch you more closely. That typically includes:
For how those risks play out over time, see recurrence and metastasis risk.
A "high-risk" SCC is one whose measurable features — size, depth, differentiation, perineural invasion, growth pattern, location — add up to a real chance of recurrence or spread. Staging systems exist to make that judgment consistent: AJCC8 is the official framework for head and neck tumors, while the BWH system does a better job of concentrating the serious outcomes into a small high-stage group, and NCCN risk categories layer in the clinical context.
If you have been told your SCC is high-risk, ask exactly which features drove that label. Understanding your specific risk profile is what lets you weigh in on how aggressively it should be treated and how closely you should be followed.
Disclaimer: This article is for educational purposes only and not a substitute for professional medical advice. Only your pathology report and treating physician can determine your tumor's stage and risk category.
Chat with our AI guide for information about high-risk squamous cell carcinoma
Chat with the Navigator